Cannell & Spears’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Cannell & Spears’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,115	Closed	-$7.84K	–	237
2022 Q4	$7.84K	Hold	2,115	–	–	﹤0.01%	224
2022 Q3	$11K	Sell	2,115 -123	-5%	-$685	﹤0.01%	192
2022 Q2	$13K	Hold	2,238	–	–	﹤0.01%	210
2022 Q1	$16K	Hold	2,238	–	–	﹤0.01%	226
2021 Q4	$30K	Buy	2,238 +698	+45%	+$11.5K	﹤0.01%	226
2021 Q3	$35K	Buy	+1,540	New	+$45.8K	﹤0.01%	240

Other funds holding ORTX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Kapitalo Investimentos Sao Paulo, Brazil $531M AUM 25.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Cannell & Spears's ORTX Position: Q1 2023 in Review

Cannell & Spears sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2023, closing a stake of 2,115 shares — an estimated $7.84K sold.

Cannell & Spears first reported a position in ORTX in Q3 2021 and held it in 6 quarters. The position peaked at $35K in Q3 2021. 35 funds tracked by Wall St. Rank hold ORTX as of Q1 2023.

Cannell & Spears reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2023 after selling out during the quarter.
Cannell & Spears sold 2,115 Orchard Therapeutics plc American Depositary Shares shares in Q1 2023, an estimated $7.84K.
Cannell & Spears first reported a position in Orchard Therapeutics plc American Depositary Shares in Q3 2021 and held it in 6 quarters.
Cannell & Spears's Orchard Therapeutics plc American Depositary Shares position peaked at $35K in Q3 2021.
35 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2023.

Based on Cannell & Spears's 13F filing for Q1 2023, filed 15 May 2023.